News|Articles|January 22, 2025
Identify Optimal Biologic Candidates: Low Volume, Early Stage Developability Assessment with Aura PTx
Author(s)Halo Labs
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
FDA Decision Accelerates Rare Disease Gene Therapy Regulatory Pathways
2
How Mitigation and Maintenance Protect Against Future Risk
3
New Cord Blood Stem Cell Approval Alters Biopharma Manufacturing Priorities
4
Behind the Headlines Episode 29: 2025 Year in Review
5
